Results 81 to 90 of about 8,463 (257)

Every‐other‐day palonosetron plus aprepitant for prevention of emesis following induction chemotherapy for acute myeloid leukemia: A randomized, controlled study from the “Rete Ematologica Pugliese”

Cancer Medicine, 2020
Background Compared with older 5‐HT3 receptor antagonists, palonosetron requires fewer drug administrations to prevent chemotherapy‐induced nausea and vomiting (CINV) following multiple‐day chemotherapy.
Nicola Di Renzo, Lorella Melillo, Fernando Porretto, Michela Dargenio, Vincenzo Pavone, Domenico Pastore, Patrizio Mazza, Donato Mannina, Anxur Merenda, Nicola Cascavilla, Giuseppina Greco, Rosella Matera, Erminio Bonizzoni, Luigi Celio, Maurizio Musso   +14 more
doaj   +1 more source

Assessing the impact of aprepitant and ondansetron on postoperative nausea and vomiting in orthognathic surgeries: a randomized controlled trial

BMC Anesthesiology, 2023
Background Postoperative nausea and vomiting (PONV) is a common side effect associated with general anesthesia. Both ondansetron and aprepitant been effectively used to prevent PONV.
Mostafa Alam, Alireza Shakeri, Ardeshir Khorsand, Karim Nasseri, Sadaf Nasseri   +4 more
doaj   +1 more source

Effects of Modification of Pain Protocol on Incidence of Post Operative Nausea and Vomiting. [PDF]

, 2016
BackgroundA Perioperative Surgical Home (PSH) care model applies a standardized multidisciplinary approach to patient care using evidence-based medicine to modify and improve protocols.
Ahn, Kyle, Bahn, Esther, Calderon, Michael-David, Harrington, Brian, Rinehart, Joseph B, Schwarzkopf, Ran, Sharfman, Zachary T, Snir, Nimrod   +7 more
core   +2 more sources

Clinical‐Pharmacological Drug Information Center of Hannover Medical School: Update From a Tertiary Care University Hospital (2022–2024)

Pharmacology Research &Perspectives, Volume 14, Issue 2, April 2026.
ABSTRACT Drug information centers (DICs) are institutions dedicated to providing independent and up‐to‐date information on medications and their usage to healthcare professionals. Here, we provide an update from the clinical‐pharmacological DIC of Hannover Medical School, covering the period from April 2022 to December 2024.
Johannes Heck, Dirk O. Stichtenoth, Christoph Schröder, Ruxandra Sabau, Anna‐Leena K. Heim, Felix Koop, Thorben Pape, Sebastian Schröder, Martin Schulze Westhoff, Benjamin Krichevsky, Martin Klietz, Stephan Greten, Carsten Schumacher   +12 more
wiley   +1 more source

Minimal renal toxicity after Rituximab DHAP with a modified cisplatin application scheme in patients with relapsed or refractory diffuse large B-cell lymphoma [PDF]

, 2016
Background: Rituximab (R) in combination with DHAP is a widely accepted salvage regimen for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
A. D. Ho, AS Levey, B Coiffier, BD Cheson, C Gisselbrecht, F. McClanahan, J Lignon, JW Friedberg, K. Lisenko, M Pfreundschuh, M. A. Schwarzbich, M. Cremer, M. Witzens-Harig, O Kanat, T Philip, T Schmitt, T. Dittrich, T. Schöning, TE Witzig, TM Habermann, WS Velasquez   +20 more
core   +2 more sources

Timing of Antidepressant Use Influences Long Term Functional Status in New Zealand Stroke Patients: A Retrospective Population Level Study

Journal of the Royal Society of New Zealand, Volume 56, Issue 2, April 2026.
This retrospective analysis explored the relationship between the timing of antidepressant use and long‐term functional status after stroke. We used linked health administrative data from a cohort of adult stroke patients in New Zealand. Demographics and prescription information were obtained from the National Minimum Dataset and Pharmaceutical ...
Shivankar Nair, Emma M. Tuckey, Deepak Gupta, Rong Liu, Alesha J. Smith, Ailsa L. McGregor   +5 more
wiley   +1 more source

Synergistic drug combinations from electronic health records and gene expression. [PDF]

, 2016
ObjectiveUsing electronic health records (EHRs) and biomolecular data, we sought to discover drug pairs with synergistic repurposing potential. EHRs provide real-world treatment and outcome patterns, while complementary biomolecular data, including ...
Chen, William, Daugherty, Aaron C, Desai, Manisha, Farrington, Carl, Gomez, Scarlett L, Hastie, Trevor, Kenkare, Pragati, Kurian, Allison W, Lim, Michael, Low, Yen S, Mathur, Maya, Radin, Andrew A, Schroeder, Elizabeth A, Seto, Tina, Shah, Nigam H, Sirota, Marina, Sledge, George W, Thompson, Caroline A, Weber, Susan, Yu, Peter P   +19 more
core   +2 more sources

Managing Skin Side Effects Associated With Oncology Treatments: Asian Perspective on Use of Dermocosmetics

Asia-Pacific Journal of Clinical Oncology, Volume 22, Issue 2, Page 186-198, April 2026.
Skin adverse events (AEs) frequently accompany all types of anticancer treatments. This publication discusses how recent international guidance on best‐practices use of dermocosmetics can be adapted to the North Asia region (China, Hong Kong, Japan, Republic of Korea, and Taiwan).
Meng Pan, Jianguo Sun, Makoto Kawashima, You Chan Kim, Mison Chun, Chia‐Yu Chu, Yi‐Hsin Liang, Mee Chang, Delphine Kerob, Brigitte Dreno   +9 more
wiley   +1 more source

Cost-effectiveness of an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer in the UK

Cancer Management and Research, 2013
Samantha Humphreys,1 James Pellissier,2 Alison Jones3 1Market Access Department, Merck Sharp and Dohme Ltd, Hoddesdon, Hertfordshire, UK; 2Health Economic Statistics, Merck Research Laboratories, Upper Gwynedd, PA, USA; 3Department of Medical Oncology ...
Humphreys S, Pellissier J, Jones A
doaj  

Comparison of Pharmacokinetics of Aprepitant in Healthy Chinese and Caucasian Subjects

Drug Design, Development and Therapy, 2020
Meng-Jie Yang, Hong-Rong Xu, Hui Li, Wei-Li Chen, Fei Yuan, Xue-Ning Li Department of Clinical Pharmacology, Zhongshan Hospital, Fudan University, Shanghai, People’s Republic of ChinaCorrespondence: Xue-Ning LiDepartment of Clinical Pharmacology ...
Yang MJ, Xu HR, Li H, Chen WL, Yuan F, Li XN   +5 more
doaj